{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T07:18:15Z","timestamp":1778397495878,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20170804"],"award-info":[{"award-number":["20170804"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20170686"],"award-info":[{"award-number":["20170686"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jacc.2021.01.045","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T02:53:42Z","timestamp":1616468022000},"page":"1535-1550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery\u00a0Disease"],"prefix":"10.1016","volume":"77","author":[{"given":"Daniel P.","family":"Andersson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Landucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ylva Trolle","family":"Lagerros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Grotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rino","family":"Bellocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Lehtihet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Holzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.01.045_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4065\/84.2.108","article-title":"A\u00a0population-based, longitudinal study of erectile dysfunction and future coronary artery disease","volume":"84","author":"Inman","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2021.01.045_bib2","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1001\/jama.294.23.2996","article-title":"Erectile dysfunction and subsequent cardiovascular disease","volume":"294","author":"Thompson","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.01.045_bib3","first-page":"2445","article-title":"Erectile dysfunction and mortality","volume":"6","author":"Araujo","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.jacc.2021.01.045_bib4","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jacc.2010.04.067","article-title":"Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial","volume":"56","author":"Batty","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.01.045_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.ijir.3901604","article-title":"Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study","volume":"20","author":"Schouten","year":"2008","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.jacc.2021.01.045_bib6","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/2047487317718082","article-title":"Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: a nationwide cohort study","volume":"24","author":"Vestergaard","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2021.01.045_bib7","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/heartjnl-2015-309223","article-title":"Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality","volume":"102","author":"Anderson","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2021.01.045_bib8","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/heartjnl-2016-310746","article-title":"Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction","volume":"103","author":"Andersson","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2021.01.045_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jacc.2011.07.051","article-title":"Cardiac uses of phosphodiesterase-5 inhibitors","volume":"59","author":"Schwartz","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.01.045_bib10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jacc.2021.01.045_bib11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities\u00a0for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacc.2021.01.045_bib12","doi-asserted-by":"crossref","unstructured":"Bohula EA, Bonaca MP, Braunwald E, et\u00a0al. Atherothrombotic risk stratification and the efficacy and safety of Vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction. 2016;134:304\u201313.","DOI":"10.1161\/CIRCULATIONAHA.115.019861"},{"key":"10.1016\/j.jacc.2021.01.045_bib13","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2021.01.045_bib14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacc.2021.01.045_bib15","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2007.10.069","article-title":"Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors","volume":"51","author":"Gazzaruso","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.01.045_bib16","first-page":"176","article-title":"Is sex only for the healthy and wealthy?","volume":"4","author":"Str\u00f6berg","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.jacc.2021.01.045_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11886-017-0917-z","article-title":"Socioeconomic status and cardiovascular disease: an update","volume":"19","author":"de Mestral","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacc.2021.01.045_bib18","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jacc.2011.06.024","article-title":"Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies","volume":"58","author":"Dong","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.01.045_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.annepidem.2005.06.047","article-title":"Cardiovascular risk among men seeking help for erectile dysfunction","volume":"16","author":"Frantzen","year":"2006","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.jacc.2021.01.045_bib20","doi-asserted-by":"crossref","first-page":"H1263","DOI":"10.1152\/ajpheart.00324.2002","article-title":"Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits","volume":"283","author":"Ockaili","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2021.01.045_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11010-013-1625-7","article-title":"Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil","volume":"379","author":"Ebner","year":"2013","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.jacc.2021.01.045_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.ijir.3901497","article-title":"The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size","volume":"19","author":"Sesti","year":"2007","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.jacc.2021.01.045_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10557-014-6559-0","article-title":"Tadalafil prevents acute heart failure with reduced ejection fraction in mice","volume":"28","author":"Salloum","year":"2014","journal-title":"Cardiovasc Drug Ther"},{"key":"10.1016\/j.jacc.2021.01.045_bib24","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/eurheartj\/eht112","article-title":"Erectile dysfunction in the cardiovascular patient","volume":"34","author":"Vlachopoulos","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.01.045_bib25","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1681\/ASN.2015050473","article-title":"Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy","volume":"27","author":"Scheele","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721002400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721002400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:38:46Z","timestamp":1760017126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721002400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0735109721002400"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.01.045","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery\u00a0Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.01.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}